Metacrine (MTCR) Commences Phase 2a Trial of MET642 for Treatment of Patients with NASH

Go back to Metacrine (MTCR) Commences Phase 2a Trial of MET642 for Treatment of Patients with NASH
(NASDAQ: MTCR) Delayed: 3.39 --0 (-0%)
Previous Close $3.39    52 Week High
Open $3.39    52 Week Low
Day High $3.39    P/E N/A 
Day Low $3.39    EPS
Volume 48,389